| Symbol | SYMQY |
|---|---|
| Name | SYMBIO PHARMACEUTICALS LTD |
| Sector | UNDEFINED |
| Region | Asia |
| Industry | - |
| Address | 105-0001 Japan Toranomon Towers Office 4-1-28 Toranomon |
| Telephone | +81 3-5472-1125 |
| Fax | — |
| — | |
| Website | https://www.symbiopharma.com/ |
| Incorporation | JP |
| Incorporated On | 2005 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Tokyo Stock Exchange |
| CIK | 0001625751 |
| Description | SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Mr. Masaru Taguchi). SymBios underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs. Additional info from OTC: |
No news found.